A Perspective From Industry – A Conversation With Richard S. Geary, Ph.D. Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals
Speaker: Richard S. Geary, Ph.D. Date: February 10, 2022 Time: 11-12 EST Description: The OTS Webinar series is pleased to feature Dr. Richard Geary, the current President Elect, and the Executive Vice President, Chief Development Officer at Ionis Pharmaceuticals. For part of the webinar ...
A Conversation with OTS President, Prof. David Corey
Speaker: David Corey, Ph.D. Date: January 13, 2022 Time: 11-12 EST Description: Join us for an open discussion on the future of the OTS. Prof. David Corey will share his vision for, and answer questions about the OTS. Hosted by former trainee reps, Ronald ...
Development of N=1 RNA Therapies in the Netherlands and Europe
After the development of Milasen in the United States, there has been an increase in the development of antisense oligonucleotide therapies for patients with unique mutations.
2021 OTS Annual Meeting Poster Winner Showcase
Date: October 29th, 2021 Time: 7am-9am Pacific/ 10am-12pm Eastern/ 4pm-6pm Central European Time Description: Are you having post-event letdown now that the annual OTS meeting is over? We are too! Join us for this special 2-hour webinar to see presentations by four poster award ...
Presentations & Networking in a Virtual World
Presenter: Aurélie Lacroix, PhD, Sixfold Bioscience Keith T. Gagnon, Ph.D, Southern Illinois University School of Medicine Date: 25 August 2021 Time: 8am Pacific / 11am Eastern / 5m Central Description: Join us for a presentation of tips & tricks for making the most of ...
Maximize Your Involvement in the OTS Community
Presenter: Erin M. McConnell, Ph.D.,University of Ottawa Annemieke Aartsma-Rus, PhD, OTS President,Leiden University Medical Center Date: June 24, 2021 Time: 8am Pacific/11am Eastern/5pm Central European Time Description: Do you study how oligonucleotides can be used as therapeutics? Are you new to the OTS? ...
How to test for immune activation by your therapeutic oligonucleotide
Presenter: Arthur M. Krieg, MD, Checkmate Pharmaceuticals Date: 19 April 2018 Description: RNA and DNA oligonucleotides with charged backbones commonly cause immune activation, which can be recognized by appropriate in vitro and/or in vivo testing. Eukaryotic innate immune systems have evolved multiple receptors to ...
Designing siRNAs for improving their therapeutic applications
Presenter: Dr. Annabelle Biscans (AstraZeneca) Date: January 27th, 2021 Description: Small interfering RNAs (siRNAs) have the potential to revolutionize medicine due to their potency, duration of effect, and ability to target previously “undruggable” disease genes. The clinical success of siRNAs is dependent on their ...
Making medicines out of pre-mRNA splicing modulators
Presenter: Isabel Aznarez, Ph.D. Stoke Therapeutics Date: April 29th, 2021 Description: Splicing is the process that edits precursor-messenger RNA (pre-mRNA) to generate the messenger RNA (mRNA) that carries the code from the nucleus to the cytoplasm where the ribosomes will translate it into a ...
The N-Lorem Foundation
Presenter: Stanley T. Crooke, MD, PhD Ionis Pharmaceuticals Date: February 9th, 2021 Description: The purpose of this presentation is to formally introduce n-Lorem to OTS and to summarize progress since being founded in January 2020. Recording of the webinar: Click play to view ...
